Huge numbers of VAERS injury reports on this vaccine
and now this
"former Wyeth manufacturing manager Mark Livingston has
filed a lawsuit against the company and two employees,
saying that in its drive to get Prevnar to the market, Wyeth
cut production corners that violate Food and Drug
Administration (FDA) rules and which could leave the vaccine
vulnerable to problems with quality control"
immunizationinfo.orgnewsbriefs detailOpen ↗
.cfv?id=9835
Lawsuit Alleges Irregularities With Vaccine
Wall Street Journal C1 Hensley, Scott ; McKay, Betsy
03/31/2004
Since its introduction to the market in 2000, the
pneumococcal vaccine Prevnar has grown in popularity as a
protective barrier against the bacteria, which can cause
brain infections and even death, yet its maker Wyeth has run
into a string of production problems that have left the
company unable to meet demand and prompting the Centers for
Disease Control and Prevention to recommend delays in
children's four-dose immunization schedules so that infants
can have at least some protection with two doses. The
vaccine takes a year to produce, so any improvement in
Wyeth's production abilities is delayed on the market for a
year, leading to continued shortages that are expected
through the summer of 2004, though the company claims that
at that time, the troubles will be over. In a twist,
however, former Wyeth manufacturing manager Mark Livingston
has filed a lawsuit against the company and two employees,
saying that in its drive to get Prevnar to the market, Wyeth
cut production corners that violate Food and Drug
Administration (FDA) rules and which could leave the vaccine
vulnerable to problems with quality control. Livingston
brought up his concerns at an FDA meeting in July 2003, but
he said that because he had not heard any development from
the agency since that time, he would go ahead with a civil
lawsuit to bring more attention to the matter, claiming that
Wyeth's actions amount to fraud against its shareholders by
not revealing problems with Prevnar production.